Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 48

1.

Basic and clinical pharmacology of new motility promoting agents.

Galligan JJ, Vanner S.

Neurogastroenterol Motil. 2005 Oct;17(5):643-53. Review.

2.

Management of irritable bowel syndrome: novel approaches to the pharmacology of gut motility.

Scarpignato C, Pelosini I.

Can J Gastroenterol. 1999 Mar;13 Suppl A:50A-65A. Review.

PMID:
10202210
3.

Promotility medications--now and in the future.

Karamanolis G, Tack J.

Dig Dis. 2006;24(3-4):297-307. Review.

PMID:
16849857
4.

Serotonin and its role in colonic function and in gastrointestinal disorders.

Costedio MM, Hyman N, Mawe GM.

Dis Colon Rectum. 2007 Mar;50(3):376-88. Review.

PMID:
17195902
5.

New-generation 5-HT4 receptor agonists: potential for treatment of gastrointestinal motility disorders.

Manabe N, Wong BS, Camilleri M.

Expert Opin Investig Drugs. 2010 Jun;19(6):765-75. doi: 10.1517/13543784.2010.482927. Review.

PMID:
20408739
6.

Renzapride: a new drug for the treatment of constipation in the irritable bowel syndrome.

Scarpellini E, Tack J.

Expert Opin Investig Drugs. 2008 Nov;17(11):1663-70. doi: 10.1517/13543784.17.11.1663 . Review.

PMID:
18922103
7.
8.

Potential of ghrelin as a therapeutic approach for gastrointestinal motility disorders.

Peeters TL.

Curr Opin Pharmacol. 2006 Dec;6(6):553-8. Review.

PMID:
17011824
9.

Role of serotonin in gastrointestinal physiology and pathology.

Cirillo C, Vanden Berghe P, Tack J.

Minerva Endocrinol. 2011 Dec;36(4):311-24. Review.

PMID:
22322654
10.

Drugs acting on serotonin receptors for the treatment of functional GI disorders.

Tonini M, Pace F.

Dig Dis. 2006;24(1-2):59-69. Review.

PMID:
16699264
11.

The rationale, efficacy and safety evidence for tegaserod in the treatment of irritable bowel syndrome.

McLaughlin J, Houghton LA.

Expert Opin Drug Saf. 2006 Mar;5(2):313-27. Review.

PMID:
16503751
12.

5-HT4 receptor agonists: similar but not the same.

De Maeyer JH, Lefebvre RA, Schuurkes JA.

Neurogastroenterol Motil. 2008 Feb;20(2):99-112. doi: 10.1111/j.1365-2982.2007.01059.x. Review.

13.

Development of drugs for gastrointestinal motor disorders: translating science to clinical need.

Sanger GJ, Alpers DH.

Neurogastroenterol Motil. 2008 Mar;20(3):177-84. doi: 10.1111/j.1365-2982.2008.01084.x. Review.

14.

Prokinetics and fundic relaxants in upper functional GI disorders.

Tack J.

Curr Opin Pharmacol. 2008 Dec;8(6):690-6. doi: 10.1016/j.coph.2008.09.009. Review.

PMID:
18940266
15.

Review article: promotility drugs in the treatment of gastro-oesophageal reflux disease.

Ramirez B, Richter JE.

Aliment Pharmacol Ther. 1993 Feb;7(1):5-20. Review.

PMID:
8094981
16.

Tegaserod: a new 5-HT4 agonist.

Lacy BE, Yu S.

J Clin Gastroenterol. 2002 Jan;34(1):27-33. Review.

PMID:
11743242
18.
19.

Translating 5-HT receptor pharmacology.

Sanger GJ.

Neurogastroenterol Motil. 2009 Dec;21(12):1235-8. doi: 10.1111/j.1365-2982.2009.01425.x. Review.

20.

Alvimopan, a selective peripherally acting mu-opioid antagonist.

Camilleri M.

Neurogastroenterol Motil. 2005 Apr;17(2):157-65. Review.

Items per page

Supplemental Content

Support Center